Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019
Abstract Background High fasting plasma glucose (FPG) has been listed as one of the risk factors for bladder cancer. We here estimated the global, regional, and national levels of bladder cancer burden attributable to high FPG from 1990 to 2019. Methods Bladder cancer data attributable to high FPG w...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6219 |
| _version_ | 1797361236598325248 |
|---|---|
| author | Ying Wu Yujiao Deng Zhijun Dai Yubo Ma Lijuan Lyu Chen Lei Yi Zheng Yizhen Li Ziming Wang Jie Gao |
| author_facet | Ying Wu Yujiao Deng Zhijun Dai Yubo Ma Lijuan Lyu Chen Lei Yi Zheng Yizhen Li Ziming Wang Jie Gao |
| author_sort | Ying Wu |
| collection | DOAJ |
| description | Abstract Background High fasting plasma glucose (FPG) has been listed as one of the risk factors for bladder cancer. We here estimated the global, regional, and national levels of bladder cancer burden attributable to high FPG from 1990 to 2019. Methods Bladder cancer data attributable to high FPG were extracted from the Global Burden of Disease Study 2019, and analyzed by age, sex, year, and location. Age‐standardized rates were utilized to evaluate the burden between different populations. The temporal trend of the burden was estimated through the Joinpoint analysis. Results In 2019, high FPG contributed to 22,823.33 (95% uncertainty interval [UI], 4694.88–48,962.26) deaths and 399,654.91 (95% UI, 81,609.35–865,890.95) disability‐adjusted life years (DALYs) of bladder cancer globally. Since 1990, the global age‐standardized death and DALY rates of bladder cancer attributable to high FPG increased apparently by 39.18% and 41.48%, respectively. During the last 30 years, high FPG‐related age‐standardized death and DALY rates of bladder cancer have increased in all countries. In 2019, Central Europe showed the greatest high FPG‐related age‐standardized death and DALY rates of bladder cancer, but Andean Latin America had the lowest rates. Nationally, Lebanon showed the greatest high FPG‐related age‐standardized death and DALY rates of bladder cancer in 2019. High FPG‐attributable deaths and DALYs of bladder cancer were more considerable among males and older people. Countries with high SDI showed higher levels of age‐standardized death and DALY rates of bladder cancer due to high FPG and presented remarkable upward trends in rates in the last 30 years. Conclusions Globally, the high FPG‐associated bladder cancer burden has remarkably increased in all countries, and showed a higher level among countries with higher SDI. Monitoring FPG levels among patients with bladder cancer is critical to lower the corresponding burden. |
| first_indexed | 2024-03-08T15:51:01Z |
| format | Article |
| id | doaj.art-acacf3824f60467fad02cbf626f22df9 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-08T15:51:01Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-acacf3824f60467fad02cbf626f22df92024-01-09T05:41:08ZengWileyCancer Medicine2045-76342023-08-011215164691648110.1002/cam4.6219Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019Ying Wu0Yujiao Deng1Zhijun Dai2Yubo Ma3Lijuan Lyu4Chen Lei5Yi Zheng6Yizhen Li7Ziming Wang8Jie Gao9Department of Urology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Nephrology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Breast Surgery The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou ChinaDepartment of Urology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Oncology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Endocrinology The General Hospital of Ningxia Medical University Yinchuan ChinaDepartment of Nephrology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Oncology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Urology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Nephrology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaAbstract Background High fasting plasma glucose (FPG) has been listed as one of the risk factors for bladder cancer. We here estimated the global, regional, and national levels of bladder cancer burden attributable to high FPG from 1990 to 2019. Methods Bladder cancer data attributable to high FPG were extracted from the Global Burden of Disease Study 2019, and analyzed by age, sex, year, and location. Age‐standardized rates were utilized to evaluate the burden between different populations. The temporal trend of the burden was estimated through the Joinpoint analysis. Results In 2019, high FPG contributed to 22,823.33 (95% uncertainty interval [UI], 4694.88–48,962.26) deaths and 399,654.91 (95% UI, 81,609.35–865,890.95) disability‐adjusted life years (DALYs) of bladder cancer globally. Since 1990, the global age‐standardized death and DALY rates of bladder cancer attributable to high FPG increased apparently by 39.18% and 41.48%, respectively. During the last 30 years, high FPG‐related age‐standardized death and DALY rates of bladder cancer have increased in all countries. In 2019, Central Europe showed the greatest high FPG‐related age‐standardized death and DALY rates of bladder cancer, but Andean Latin America had the lowest rates. Nationally, Lebanon showed the greatest high FPG‐related age‐standardized death and DALY rates of bladder cancer in 2019. High FPG‐attributable deaths and DALYs of bladder cancer were more considerable among males and older people. Countries with high SDI showed higher levels of age‐standardized death and DALY rates of bladder cancer due to high FPG and presented remarkable upward trends in rates in the last 30 years. Conclusions Globally, the high FPG‐associated bladder cancer burden has remarkably increased in all countries, and showed a higher level among countries with higher SDI. Monitoring FPG levels among patients with bladder cancer is critical to lower the corresponding burden.https://doi.org/10.1002/cam4.6219bladder cancerDALYdeathhigh fasting plasma glucose |
| spellingShingle | Ying Wu Yujiao Deng Zhijun Dai Yubo Ma Lijuan Lyu Chen Lei Yi Zheng Yizhen Li Ziming Wang Jie Gao Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019 Cancer Medicine bladder cancer DALY death high fasting plasma glucose |
| title | Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019 |
| title_full | Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019 |
| title_fullStr | Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019 |
| title_full_unstemmed | Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019 |
| title_short | Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019 |
| title_sort | estimates of bladder cancer burden attributable to high fasting plasma glucose findings of the global burden of disease study 2019 |
| topic | bladder cancer DALY death high fasting plasma glucose |
| url | https://doi.org/10.1002/cam4.6219 |
| work_keys_str_mv | AT yingwu estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT yujiaodeng estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT zhijundai estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT yuboma estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT lijuanlyu estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT chenlei estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT yizheng estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT yizhenli estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT zimingwang estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 AT jiegao estimatesofbladdercancerburdenattributabletohighfastingplasmaglucosefindingsoftheglobalburdenofdiseasestudy2019 |